Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00199082
Status:
COMPLETED
Last Update Posted:
2022-08-19
First Post:
2005-09-12
Brief Title:
Newly Diagnosed Mature B-ALL Burkitts Lymphoma and Other High-grade Lymphoma in Adults
Sponsor:
Nicola Goekbuget
Organization:
Goethe University
Study Overview
Official Title:
Multicenter Study to Optimise Therapy of B-ALL Burkitts NHL and High-Grade Non-Hodgkins Lymphoma in Adults Amend 7
Status:
COMPLETED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients followed by local radiation therapy in the case of initial mediastinal or central nervous system CNS involvement or a residual tumor after chemotherapy A dose-reduced regimen is offered for patients estimated to be over 55 years biologically
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None